Predicted protein targets (top 10)
| gene | UniProt | supporting neighbours | confidence | |
|---|---|---|---|---|
| ▸ | GPR35 | Q9HC97 | 1/20 | 0.44 |
| ▸ | STK33 | Q9BYT3 | 11/20 | 0.42 |
| ▸ | POLB | P06746 | 2/20 | 0.42 |
| ▸ | TDP1 | Q9NUW8 | 1/20 | 0.42 |
| ▸ | MEN1 | O00255 | 3/20 | 0.41 |
| ▸ | KMT2A | Q03164 | 3/20 | 0.41 |
| ▸ | GRIK1 | P39086 | 1/20 | 0.40 |
| ▸ | RAB9A | P51151 | 1/20 | 0.39 |
| ▸ | SMN1; SMN2 | Q16637 | 1/20 | 0.39 |
| ▸ | L3MBTL1 | Q9Y468 | 1/20 | 0.38 |
Click a target to see other patent compounds predicted against it — the reverse direction, in place.
Similar compounds — the chemically nearest patent molecules
Nearest neighbours by Morgan-fingerprint cosine across the patent-compound collection, with each neighbour's top predicted target and the predicted targets it shares with this molecule.
| Compound | similarity | top predicted | shared targets | |
|---|---|---|---|---|
| SCHEMBL6710126 | 0.90 | STK33 (0.52) | STK33POLBTDP1MEN1KMT2A | |
| SCHEMBL6713921 | 0.89 | MAPT (0.43) | POLBTDP1MEN1KMT2AGRIK1 | |
| SCHEMBL6708679 | 0.89 | GRIK1 (0.44) | GPR35POLBTDP1GRIK1 | |
| SCHEMBL7199402 | 0.88 | STK33 (0.40) | STK33POLBTDP1MEN1KMT2A | |
| SCHEMBL6713760 | 0.87 | GRIK1 (0.42) | GPR35STK33TDP1MEN1KMT2A | |
| SCHEMBL6708757 | 0.87 | GRIK1 (0.42) | GPR35POLBTDP1MEN1KMT2A | |
| SCHEMBL6710166 | 0.86 | NPC1 (0.43) | GRIK1RAB9ASMN1; SMN2 | |
| SCHEMBL6709215 | 0.85 | MEN1 (0.55) | POLBMEN1KMT2AGRIK1RAB9A | |
| SCHEMBL6713262 | 0.85 | GRIK1 (0.41) | GPR35POLBTDP1MEN1KMT2A | |
| SCHEMBL6713931 | 0.85 | GRIK1 (0.41) | GPR35TDP1MEN1KMT2AGRIK1 |
Similarity is cosine over the 2,048-bit Morgan fingerprint (≈ Tanimoto). Identical fingerprints score 1.00.
Patent provenance — the patents this molecule appears in, and who filed them
Claimed or disclosed in 2 patents. claimed = in the patent's claims; disclosed = body only.
| Patent | Title | Assignee | Published | Priority | Filing | Country | Status |
|---|---|---|---|---|---|---|---|
| US-20040142981-A1 | Antibacterial benzoic acid derivatives | PHARMACIA & UPJOHN COMPANY | 2004-07-22 | — | — | US | disclosed |
| WO-2004018461-A2 | ANTIBACTERIAL BENZOIC ACID DERIVATIVES | PHARMACIA & UPJOHN COMPANY LLC (US) | 2004-03-04 | — | — | WO | disclosed |
Patent text — is the patent's own abstract consistent with the prediction?
For each of this compound's patents that has machine-readable text (1 of them — usually the abstract, not the full specification), we ask MedCPT which protein the text reads most about, and where the chemistry-predicted target lands among 4885 human targets. A high rank means the patent's own wording is consistent with the prediction — a weak, independent signal, not proof of activity.
| Patent | Title | Text reads most about | Predicted target · text-rank |
|---|---|---|---|
| US-20040142981-A1 | Antibacterial benzoic acid derivatives | GABRD, PHB1, GABBR1 | GPR35 2928/4885STK33 3606/4885POLB 626/4885 |
“Text reads most about” is the patent abstract's nearest protein in MedCPT space (background-debiased). Only ~1.4% of patents have machine-readable text, so most compounds won't have this panel.